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Abstract 16 
Synapse loss is an early feature shared by many neurodegenerative diseases, and it represents the 17 
major correlate of cognitive impairment. Recent studies reveal that microglia and astrocytes play a 18 
major role in synapse elimination, contributing to network dysfunction associated with 19 
neurodegeneration. Excitatory and inhibitory activity can be affected by glia-mediated synapse loss, 20 
resulting in imbalanced synaptic transmission and subsequent synaptic dysfunction. Here we review 21 
the recent literature on the contribution of glia to excitatory/inhibitory imbalance, in the context of 22 
the most common neurodegenerative disorders. A better understanding of the mechanisms 23 
underlying pathological synapse loss will be instrumental to design targeted therapeutic interventions, 24 
taking in account the emerging roles of microglia and astrocytes in synapse remodeling. 25 
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1. Introduction 1 
The prevalence of neurodegenerative disorders has been rapidly increasing over the past decades. 2 
These untreatable and often lethal conditions including Alzheimer’s disease (AD), Parkinson’s disease 3 
(PD), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), affect over 100 million people 4 
worldwide (Baxter et al., 2015; Prince et al., 2013; Browne et al., 2014). Despite differences in age of 5 
onset and genetic risk factors associated with the disease, common pathophysiological features can 6 
be identified, including synaptic and glial dysfunction, as well as cognitive impairments. Synapse loss 7 
is an early occurring hallmark in many neurodegenerative disorders, which correlates best with the 8 
appearance and progression of cognitive decline (DeKosky and Scheff, 1990; Terry et al., 1991, Koffie 9 
et al., 2011, Spires-Jones and Hyman, 2014). Abnormal glial function is also recognized as an early 10 
pathological feature commonly observed in neurodegenerative disease (Verkhratsky et al., 2014). 11 
However, for a long time, the prevailing neuro-centric view of pathogenesis has led to the 12 
underestimation of key roles for non-neuronal cells in the brain, primarily glia, which were instead 13 
considered as mere bystanders or secondary responders in the pathological process. Only in the last 14 
decade, with the advent of new genetic, molecular and pharmacological tools, have significant steps 15 
forward been made towards our understanding of glial function, revealing a central role for these cells 16 
in disease (Verkhratsky et al., 2014).  17 
 From the Greek word ‘‘glue’’, glia in the central nervous system (CNS) include three major cell 18 
subsets: astrocytes, microglia and oligodendrocytes. While the latter are mainly responsible for the 19 
formation of myelin and for providing metabolic support to axons (Baumann and Pham-Dinh, 2001, 20 
Simons and Nave, 2015), microglia and astrocytes cover a variety of functions, ranging from trophic 21 
support to refinement and coordination of neural networks (Reemst et al., 2016, Allen and Lyons, 22 
2018). Microglia are the resident macrophages of the CNS and constitute about 10-15% of all the brain 23 
cells. Historically, they have been regarded exclusively as innate immune cells, considered to be 24 
‘activated’ only during infection or injury. In the last decade, however, several new physiological roles 25 
for microglia have been described, revealing a much broader scenario for the multifaceted tasks 26 
performed by these cells (Tremblay et al., 2011, Sierra et al., 2014, Paolicelli and Ferretti, 2017). 27 
Astrocytes are the more abundant glial cell in the CNS; their processes closely enwrap synapses, and 28 
their role in regulating synaptogenesis, neurotransmitter recycling and synaptic transmission is well 29 
established (Parpura et al., 1994, Vesce et al., 1999, Panatier et al., 2011, Chever et al., 2016). In 30 
addition, they play key roles in maintaining the blood–brain barrier, providing trophic and metabolic 31 
support to neurons (Pellerin et al., 2007, Sofroniew and Vinters, 2010). Since the recent recognition of 32 
a role for glia in refining synaptic connections, intense investigations have been devoted to elucidate 33 
the molecular mechanisms of glia-meditated synapse elimination, particularly in the context of 34 
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neurodegeneration. The majority of neurodegenerative disorders fall into the category of 1 
‘proteinopathies’, because of the characteristic accumulation of toxic protein aggregates (Ross and 2 
Poirier, 2004, Soto and Pritzkow, 2018). In such diseases, pathological proteins often accumulate at 3 
the synapse (Henstridge et al., 2018, Koffie et al., 2009, Koffie et al., 2012), thus causing synaptic 4 
dysfunction and likely rendering the synapses vulnerable and primed for removal (Walsh et al., 2002, 5 
Shankar et al., 2007, Crimins et al., 2012, Geracitano et al., 2003, Pieri et al., 2003).  In the case of AD, 6 
for instance, amyloid beta peptide accumulates at the synaptic site long before its extracellular 7 
aggregation in plaques, and it is associated with alterations in synaptic structures, both in mouse and 8 
in human studies (Gylys et al., 2004, Almeida et al., 2005, Sokolow et al., 2012, Takahashi et al., 2013).  9 
Synapse elimination could occur via autonomous pathways within the damaged neuron, due to 10 
localized caspases or necrotic signals (Wishart et al., 2006, Erturk et al., 2014) or via active non-cell-11 
autonomous removal of synapses by surrounding glial cells (Hong et al., 2016, Vasek et al., 2016, 12 
Paolicelli et al., 2017). Evidence for either scenario or even a combination of both exists. In this review 13 
we will primarily focus on glial-dependent synapse loss and revise the recent literature providing 14 
evidence for glial contribution to excitatory-inhibitory network dysfunction in pathological states. 15 
 16 
 17 
2.  Synapse remodeling in development and disease   18 
The term synapse, from the Greek συνάψις, meaning “conjunction”, refers to the physical point of 19 
contact between two neurons, and thus defines the anatomical site of information exchange between 20 
an axonal input and the recipient dendritic spine (Harris and Weinberg, 2012). Synapses are highly 21 
dynamic sub-cellular structures, as they can be rapidly formed or eliminated during plasticity-mediated 22 
processes (Engert and Bonhoeffer, 1999, Matsuzaki et al., 2001). They represent the structural basis 23 
of long-term potentiation, essential for memory formation (Matsuzaki et al., 2004). Evidence of the 24 
highly dynamic nature of synapses has been provided by advances in live imaging techniques, showing 25 
that dendritic spines rapidly appear and disappear as a result of experience-dependent plasticity upon 26 
sensory experience, and learning processes (Toni et al., 1999, Lendvai et al., 2000, Holtmaat and 27 
Svoboda, 2009, Fu et al., 2012). During early development, immature neural circuits undergo synaptic 28 
refinement, in which activity-dependent competition between synapses ultimately results in the 29 
elimination of inappropriate connections and brain plasticity, while strong synapses are reinforced 30 
(Penn et al., 1998; Lichtman and Colman, 2000, Hua and Smith, 2004, Torborg et al 2005, Mikuni et al., 31 
2013, Fields et al 2014, Robin et al 2018). Importantly, the proposed mechanism of the strongest 32 
‘winning inputs’ (Personius and Balice-Gordon, 2000) is consistent across a number of models, namely 33 
the neuromuscular junction (NMJ) (Wang et al., 2014), the Purkinje fibers in the cerebellum (Mason 34 
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and Gregory, 1984, Hashimoto and Kano, 2003, Kakegawa et al., 2015) and the retino thalamic system 1 
(Hong and Chen, 2011), suggesting that activity-dependent remodeling of synapses is a conserved 2 
process across the central and peripheral nervous system. In vivo imaging studies recently showed that 3 
monocular deprivation (MD) increases dendritic spine elimination in the developing mouse visual 4 
cortex, with no effects on synapse formation (Zhou et al., 2017). Interestingly, binocular deprivation 5 
(BD), which entirely suppresses competition between the two eyes, failed to induce synapse 6 
elimination, and resulted by contrast in enlarged dendritic spine size (Zhou et al., 2017). 7 
 The high dynamic remodeling of synapses not only occurs during early developmental stages, 8 
but also persists across the entire lifespan (Peretti et al., 2015). Live imaging of cortical regions largely 9 
supports the experience-dependent plasticity of dendritic spines in the adult mouse brain (Xu et al., 10 
2009, Yang et al., 2009). In vivo imaging of the hippocampus, a highly plastic structure, has been made 11 
possible only recently, upon novel methods of cortical tissue resection (Pilz et al., 2016). Such studies 12 
have provided evidence for network plasticity with new spines formed and eliminated in the CA1 13 
stratum radiatum, with an impressive -previously underscored- spine turnover of ~40% within 4 days 14 
(Gu et al., 2014, Pfeiffer et al., 2018). 15 
 While synapse elimination in the context of brain development and experience-dependent 16 
plasticity is a physiological process (Wolff and Missler, 1993, Kamiyama et al., 2006), its later and 17 
dysregulated occurrence is recognized as an early pathological feature of neurodegenerative diseases 18 
(DeKosky et al., 1990, Henstridge et al., 2018). Indeed, one of the earliest hallmarks of 19 
neurodegeneration is the loss of presynaptic terminals and dendritic spines, which represents the 20 
major correlate of cognitive impairment (Terry et al., 1990, Scheff et al., 2006, Scheff et al., 2014). 21 
Structural and functional alterations of synapses, culminating in synapse loss, are associated with 22 
sensory, motor, and cognitive impairments observed in a variety of neurodegenerative disorders, 23 
ranging from AD to Motor Neuron Diseases (MND), and often precede clinical manifestations (Selkoe, 24 
2002, Henstridge et al, 2018). Yet, the causes and the molecular mechanisms leading to pathological 25 
synapse loss have not been fully elucidated (Henstridge et al., 2016).  On one hand, the regenerative 26 
capacity of synapses seems to be significantly reduced in the disease state, as shown in prion-infected 27 
and AD mouse models (Peretti et al., 2015); on the other hand, aberrant synaptic pruning or lack of 28 
trophic support by surrounding glia cells can contribute to the drastic reduction in synapse number. 29 
 30 
 31 
3. Contribution of GLIA to synapse elimination   32 
Recent literature highlights glial cells as active participants in the process of neural circuits refinement. 33 
Microglia and astrocytes contribute to accurate network formation by directly pruning redundant 34 
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synapses during early development, and thus shaping brain connectivity (Paolicelli et al., 2011, Zhan 1 
et al., 2014, Chung et al., 2013, Hakim et al., 2014, Filipello et al, 2018). In addition, glia can also act 2 
indirectly to induce effects on synaptic function, via the release of soluble modulators (Chung et al 3 
2015). Compelling evidence shows that synapse elimination by glia is important in the activity-4 
dependent wiring of the brain, with microglia and astrocytes selectively removing the weaker synapses 5 
upon input competition (Schafer et al., 2012, Chung et al., 2013, Sipe et al., 2016, Yang et al., 2016). 6 
For example, the visual system is a well-characterized model for experience-dependent synaptic 7 
refinement (Wiesel and Hubel, 1963), and thus, the developing retino thalamic system has been 8 
frequently used for studying competition of synaptic inputs, which project from the retinal ganglion 9 
cells (RGCs) to the relay neurons in the dorsal later geniculate nucleus (dLGN), and then to the primary 10 
visual cortex. This model has been influential in revealing that microglia are active players in 11 
experience-dependent remodeling of neural circuits (Tremblay et al., 2010, Schafer et al., 2012, Sipe 12 
et al., 2016). Sensory deprivation, by closure of one eye, during the visual critical period results in 13 
enhanced engulfment of synaptic terminals by microglia and astrocytes (Chung et al., 2013, Sipe et al., 14 
2016), whereas binocular deprivation, achieved by pharmacological blockade, drastically reduces 15 
astrocyte-mediated synaptic pruning, further confirming that active competition of synaptic inputs is 16 
required for glial-dependent synapse remodeling (Chung et al., 2013). Several pathways have been 17 
implicated in this process, including fractalkine signaling (Cx3cr1/Cx3cl1), DAP12/ Triggering Receptor 18 
expressed on Myeloid cells 2 (TREM2) signaling and the complement pathway for synapse elimination 19 
by microglia (Paolicelli et al. 2011, Schafer et al., 2012, Filipello et al., 2018), and MEGF10 and MERTK 20 
for astrocyte-mediated synapse engulfment (Chung et al., 2013). Dysfunctional regulation of such 21 
pathways or intrinsic defects in glia are possible causes for the pathological synaptic pruning observed 22 
in neurodegeneration. Indeed, a growing body of evidence indicates that glia-mediated synapse 23 
removal becomes dysregulated in aging and disease. A prominent hypothesis is that an increased 24 
activation of the complement cascade, associated with neurodegenerative disorders, enhances 25 
complement deposition on synaptic terminals, priming the synapses for removal and thus mediating 26 
aberrant synapse elimination. In support of this, distinct animal models of neurodegeneration 27 
(discussed below) exhibit upregulated levels of complement C3 and C1q, and subsequent synapse loss 28 
(Fonseca et al., 2004; Lui et al., 2016; Shi et al., 2017a, 2015, Michailidou et al., 2015, 2017). Also, 29 
injection of amyloid-beta peptide in wild-type mice was shown to increase the levels of complement 30 
molecules, and in turn to promote synapse engulfment by microglia (Hong et al., 2016). A consistent 31 
role for complement in opsonizing synapses for removal has been shown in ageing models, with 32 
complement C3-deficient mice protected from age-related hippocampal decline (Shi et al., 2015). 33 
Complement upregulation was also reported upon viral infection. However, while such increase is 34 
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critical for mediating microglial removal of presynaptic terminals in the hippocampus of West Nile 1 
Virus (WNV) infected mice (Vasek et al., 2016), it appears dispensable in IFN- mediated microglial 2 
synaptic stripping upon lymphocytic choriomeningitis viral infection (Di Liberto et al., 2018). Type I IFN 3 
signaling instead mediates synapse elimination by microglia in a mouse model of Systemic Lupus 4 
Erythematosous (SLE), an incurable autoimmune disease (Bialas et al., 2017).  5 
Purinergic signaling also plays crucial roles in microglia-mediated synapse refinement. ATP is a 6 
major signaling molecule, that acts as a danger signal once released extracellularly and profoundly 7 
affects microglial function (Rodrigues et al., 2015, George et al., 2015). Microglial processes are rapidly 8 
directed towards sources of ATP through the activation of P2Y12 receptors (Davalos et al., 2005). 9 
Activity-dependent synapse remodeling in the developing mouse visual cortex has been shown to 10 
strongly rely on such purinergic pathways in microglia, as knockout mice exhibited defective ocular 11 
dominance plasticity (Sipe et al., 2016). In addition, calcium-mediated purinergic receptors regulate 12 
microglial phagocytoses during postnatal brain development (Sunkaria et al., 2016). 13 
Microglia not only sense and respond to ATP, but they can also serve as a source of purines, which 14 
modulate synaptic plasticity, thus representing an alternative mechanism for microglia-induced 15 
synaptic refinement (George et al., 2016). 16 
Also, intrinsic glia dysfunction caused by genetic mutations can lead to aberrant synapse 17 
elimination. Loss of progranulin was shown to promote synaptic pruning by microglia, in a C1q-18 
dependent manner (Lui et al, 2016). We have reported evidence for enhanced synapse engulfment, in 19 
the motor/somatosensory cortex of mice selectively lacking microglial TDP-43 (Paolicelli et al., 2017).  20 
Other immune-related molecules such as CD47, have been recently described to work as ‘spare me’ 21 
signals, and to protect synapses from excessive microglia-mediated pruning (Lehrman et al., 2018). 22 
 An interesting aspect that warrants further investigation is the cross-talk between microglia 23 
and astrocytes. Collecting evidence indicates that microglia can modulate astrocytic function, and 24 
conversely astrocytes can regulate microglial phenotypes (Jha et al., 2018). Microglial derived ATP, for 25 
instance, acts through the astrocytic receptor P2Y1, thus modulating excitatory neurotransmission and 26 
providing neuroprotection (Pascual et al., 2012, Shinozaki et al., 2014). Microglia can also induce 27 
neurotoxic astrocytes through the release of C1q, tumor necrosis factor-α (TNF-α), and interleukin (IL)-28 
1α (Liddelow et al., 2017). Recent findings show that astrocytic NF-kB activation induce a Wnt-29 
dependent microglial proliferation, identifying astrocytes as important regulator of microglial 30 
expansion (Ouali Alami et al., 2018). Astrocyte-mediated synapse elimination has been shown to occur 31 
soon after acute sleep deprivation, before microglia-mediated remodeling, which is engaged only 32 
subsequently, if sleep deprivation is prolonged for several hours (Bellesi et al., 2017). It is thus tempting 33 
to speculate that astrocytes and microglia can act together in coordination, to ensure efficient synapse 34 
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remodeling. Fine-tuned communication between microglia and astrocytes is crucial for proper brain 1 
functioning. Thus, a better understanding of the cellular processes involved in this cross-talk will be 2 
essential to elucidate the role of glia in the diseased brain. 3 
 Lifestyle factors related to dementia, such as nutrition, sleep quality and stress, are heavily 4 
implicated in glia-mediated synapse loss and cognitive decline (Cope et al., 2018; Rajendran and 5 
Paolicelli, 2018). On the other hand, large-scale human genetic studies have identified glia-specific 6 
genes as genetic risk factor in a range of neurological conditions from autism (Voineagu et al., 2011) 7 
to Alzheimer’s disease (Karch et al, 2015, Gosselin et al., 2017). Taken together, all this evidence reveals 8 
glia as a common link between many of the world’s most impenetrable diseases.  9 
 10 
 11 
4.  Imbalance between excitation and inhibition in pathological states   12 
The balance between the excitatory and inhibitory control of synaptic activity needs to be tightly 13 
maintained to ensure proper functioning and plasticity of neural circuits (Hensch and Fagiolini, 2005, 14 
Harauzov et al., 2010). Pre-synaptic terminals of excitatory synapses release glutamate as their major 15 
neurotransmitter, and are thus defined glutamatergic. Glutamate is received at the post-synapse by 16 
the ionotropic (N-methyl-D-aspartate receptors NMDARs and 2-amino-3-(3-hydroxy-5-methyl-17 
isoxazol-4-yl) propanoic acid receptors AMPARs) and metabotropic (mGluR) glutamate receptors. On 18 
the other hand, pre-synaptic terminals at inhibitory synapses primarily release -aminobutyric acid 19 
(GABA), and are thus defined GABAergic. GABA is post-synaptically received by ionotropic (GABAAR) 20 
and metabotropic (GABABR) GABA receptors. In terms of spatial organization, glutamatergic synapses 21 
are located almost exclusively on dendritic spines, whereas GABAergic synapses can be spread along 22 
the dendritic shaft, somata, and axon initial segments (Penzes et al., 2011, Fritschy and Brunig, 2003). 23 
Excitatory neurons increase or decrease the accumulation of glutamate receptors at synaptic sites in 24 
response to changes in their own firing rates, through what has been defined as homeostatic synaptic 25 
scaling (Turrigiano et al., 1998, Turrigiano, 2004, Turrigiano, 2008). The aim is to stabilize neuronal 26 
firing by adjusting its own synaptic strength to compensate for perturbations in surrounding neural 27 
activity (Ibata et al., 2008).  28 
Network synchrony and oscillatory brain rhythms are promoted and controlled by the activity 29 
of inhibitory GABAergic interneurons across the entire lifespan, with important cross-talks with 30 
astrocytes  modulating synaptic efficacy (Buzsaky et al., 2004, Klausberger and Somogyi, 2008, Perea 31 
et al., 2016, Sardinha et al., 2017, Mederos et al 2018 ). Indeed, in the early stages of several brain 32 
disorders, impairment in inhibitory transmission combined with possible defects in homeostatic 33 
synaptic scaling at excitatory synapses might drastically compromise the excitation/ inhibition (E/I) 34 
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balance (Palop and Mucke, 2016). Defective inhibition or aberrant excitation in brain development has 1 
been associated with severe alteration in the E/I ratio (observed in ASD for example) and considered 2 
to be causally linked to behavioral abnormalities (Rubenstein and Merzenich, 2003, Nelson and Valakh, 3 
2015, Gao and Penzes, 2015). In support of this, modulation of prefrontal cortex E/I by optogenetics 4 
has recently been shown to rescue deficits in social behavior, in a mouse model of autism 5 
(Selimbeyoglu et al., 2017). Nevertheless, in other cases with memory alterations, selective changes of 6 
glutamatergic synaptic markers, have been reported without evident changes of GABAergic synaptic 7 
markers, in models of childhood epilepsy, diabetic encephalopathy and repeated stress, supporting 8 
the complexity of this topic (Cognato et al., 2010, Duarte et al., 2012, Canas et al., 2014, Kaster et al., 9 
2015). 10 
 In neurodegeneration, such as in AD, network activities are altered even decades before 11 
clinical disease onset and are associated with diverse cognitive manifestations (Palop and Mucke, 12 
2016). To date, the mechanisms and pathophysiological consequences of these alterations, which 13 
include activation and deactivation deficits of neural circuits, are poorly understood. Importantly, 14 
recent findings suggest that network activities can be experimentally or behaviorally manipulated to 15 
improve cognitive function in AD mouse models (Sanchez et al., 2012, Busche et al., 2015), and even 16 
in patients at risk of AD (Bakker et al., 2012, Bakker et al., 2015). Overall, impairments in inhibitory 17 
connections, with consequent hyperexcitation, are emerging as potential mechanisms underlying 18 
cognitive dysfunction in several neurodegenerative diseases. On the other hand, selective increase in 19 
inhibition, via pharmacogenetic activation of parvalbumin interneurons, was recently shown to have 20 
beneficial effects, preventing stress-induced synapse loss in vivo (Chen et al., 2017).   21 
 Considering the complexity of our brain, it is easy to imagine that the fine-tuned balance 22 
between excitation and inhibition is not simply the net output of neuronal firing, but is rather the result 23 
of a highly regulated cross-talk amongst numerous cell types that are able to sense synaptic activity 24 
and to assist neurons to dynamically and appropriately adjust synapse strength and number. In this 25 
scenario, glial cells, such as astrocytes and microglia, which are known to closely interact with neural 26 
networks, can directly contribute to homeostatic synaptic scaling. Indeed, it has been proposed that 27 
glia participate directly in the homeostatic, activity-dependent regulation of synaptic connectivity 28 
through the release of TNF-, a cytokine known to increase the cell surface expression of AMPA 29 
receptors (Stellwagen and Malenka, 2006). Similarly, several other molecules released by microglia 30 
and astrocytes might exert a direct regulation of plasticity by affecting receptor composition at the 31 
synapse, such as BDNF and IL1 (Parkhurst et al., 2013, Rizzo et al., 2018).  32 
 In addition to mechanisms mediated by release of soluble factors, it would be important to investigate 33 
whether refinement of synaptic connections by glial synaptic pruning also occurs to reinforce synaptic 34 
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scaling. Growing evidence indicates that microglia are capable of sensing synaptic activity and act as 1 
key players in homeostatic regulation of neural firing (Li et al., 2012, Ji et al., 2013, Bechade et al., 2 
2013). Lipopolysaccharide (LPS) injection in mice promotes transient but selective microglia-mediated 3 
removal of inhibitory synapses, which ultimately results in neuroprotection by suppressing inhibition 4 
and increasing synchronic neural firing (Chen et al., 2014). LPS-driven inflammation has profound 5 
effects on synaptic transmission (Pickering and O'Connor, 2007). Recent studies show that short-term 6 
LPS stimulation of microglia in spinal cord specifically decreases inhibitory glycinergic post-synaptic 7 
currents (Cantaut-Belarif et al., 2017). It is thus plausible to speculate that loss of excitatory synapses 8 
could be counteracted by microglia through removal of inhibitory inputs. On the other hand, astrocytes 9 
are much less motile, but their processes are more stably associated with synapses, and even 10 
considered a constant synaptic element, forming the so-called ‘tripartite synapse’ (Araque et al., 1999). 11 
Interestingly, perturbations in astrocytic function lead to selective reduction in inhibitory, but not 12 
excitatory currents, as a consequence of rapid GABA depletion induced by downregulation of the 13 
glutamine synthetase enzyme (Ortinski et al., 2010). 14 
Astrocytes also play critical roles in activity-dependent synapse elimination, as previously discussed. In 15 
the light of such observations, glia cells represent the perfect candidates for monitoring and eventually 16 
restoring E/I networks balance, through selective remodeling of excitatory or inhibitory inputs. 17 
  Overall, a dysregulated ratio between excitation and inhibition has significant implications in 18 
behavioral outputs associated with neurodevelopmental and neurodegenerative disorders, however 19 
the exact molecular and cellular processes at the origin of such dysfunction are yet to be elucidated. 20 
In the following paragraphs we will review the recent literature, highlighting possible links between 21 
glia-mediated synaptic remodeling and dysregulation of the E/I network balance in 22 
neurodegeneration. 23 
 24 
 25 
5. Alzheimer’s disease  26 
AD is the most common cause of dementia in the elderly, and despite its increasing prevalence there 27 
are no effective treatments available. The rare familial form of AD involves mutations of the amyloid 28 
precursor protein gene (APP) and Presenilins 1 and 2 (PSEN1 and PSEN2), which cleave APP to form 29 
amyloid- (A) species (Hardy and Higgins, 1992; Chávez-Gutiérrez et al., 2012). Late-onset (LOAD), or 30 
sporadic AD accounts for more than 95% of the Alzheimer’s cases, but has no clear aetiology. With 31 
ageing being the strongest risk factor, several genetic polymorphisms in various gene loci have been 32 
associated with increased AD risk, such the Apolipoprotein E4 (ApoE4) allele or the R47H mutation in 33 
Trem2 (Roses, 1996; Guerreiro et al., 2013; Jonsson et al., 2013). AD is characterized by deposition of 34 
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extracellular A plaques, intracellular neurofibrillary tau tangles (NFTs), and progressive 1 
neurodegeneration accompanied by cognitive decline (Spires-Jones and Hyman, 2014). Several studies 2 
have focused on the pathological role of amyloid-beta (A) oligomeric species as a major player in 3 
neuronal and network dysfunction at early stages of the disease progression, thus providing a broad 4 
range of causative mechanisms (Cleary et al., 2005, Shankar et al., 2008, Li et al., 2011). For instance, 5 
A can cause E/I imbalance through disruption of fast-spiking GABAergic inputs (Ren et al., 2018). 6 
Mutations in the amyloid precursor protein APP leading to increase in A oligomerization (E693 Osaka 7 
mutation; Tomiyama et al., 2010) have also been shown to cause selective GABAergic depletion in 8 
recessive familial AD (Umeda et al., 2017). Many of the LOAD risk genes, including APOE and TREM2, 9 
involve the brain’s immune system and the majority of them are highly enriched in microglia (Gosselin 10 
et al., 2017), suggesting glial cells are causally implicated in the pathogenesis of AD, and thus might be 11 
important players in the E/I imbalance observed already in the early stages (Henstridge et al., 2019).  12 
The microglial and astrocyte reactivity in AD and their physiological role in synaptic pruning has 13 
inspired a new wave of research into glial-mediated synapse loss in AD as a driver of network 14 
dysfunction (Rodriguez et al., 2014; Serrano-Pozo et al., 2013). 15 
Other immune cells, such as lymphocytes and neutrophils may play important roles in the onset and 16 
progression of AD, also interacting with resident glia cells (Town et al., 2005, Ferretti et al., 2016, Xie 17 
and Yang 2015).  18 
 19 
5.1. Microglia and astrocytes in synapse loss in AD 20 
It is well established that excitatory synapses are vulnerable in AD. Specifically, oligomeric A (oA) 21 
not only induces synaptotoxicity but also synaptic weakening through prolonged long-term depression 22 
(LTD) and impaired long-term potentiation (LTP) (Shankar et al., 2008; Li et al., 2009; Wu et al., 2010). 23 
In turn, glutamatergic signaling deficits in AD can range from NMDA and AMPA  receptor 24 
internalization causing synaptic weakening (Zhang et al., 2003; Snyder et al., 2005) to NMDA-mediated 25 
glutamate excitotoxicity (Esposito et al., 2013). Recent reports suggest that other mechanisms of 26 
synapse dysfunction, such as the upregulation of adenosine A2A receptor might even occur before and 27 
independent of defective glutamate receptors, in a mouse model of AD (Viana da Silva et al., 2016). 28 
 Most studies demonstrating synapse loss by microglia have focused on the engulfment of pre- and 29 
post-synaptic markers, by co-localization approaches, with a preferential focus on excitatory synapses. 30 
The role of complement, in virtue of its role in mediating synaptic pruning during development, has 31 
been extensively investigated in the context of synapse elimination in AD. Indeed, in two 32 
amyloidopathy models of AD (Tg2576 and APP/PS1) crossed with C1q knockout mice, lack of C1q 33 
protected against synaptophysin loss in the hippocampus of aged mice (Fonseca et al., 2004). Similarly, 34 
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more recent work has shown increased co-localization of C1q with excitatory post-synaptic densities 1 
(PSD-95) in the J20 APP-overexpressing mouse model, as well as in transgenic APPsw/PSEN1DE9 mice, 2 
and also following injections of oA (Hong et al., 2016, Bie et al., 2019). Synaptotoxicity and LTP 3 
impairments induced by oA were also prevented in C1q knockout mice or upon administration of C1q 4 
neutralizing antibodies, suggesting C1q is critical for synaptic elimination (Hong et al., 2016, Bie et al., 5 
2019). A proposed mechanism for C1q upregulation in hippocampal synapses is via metabotropic 6 
glutamate receptor signaling (mGluR1) (Bie et al., 2019), which has been shown to be involved in 7 
synaptic LTD upon amyloid challenge (Chen et al., 2013). Overall, upregulation in complement 8 
molecules is associated with higher internalization of synaptic markers by microglia and with overall 9 
synaptic loss. In agreement with these outcomes, APP/PS1 mice lacking C3 showed a milder pro-10 
inflammatory biochemical and morphological profile, reduced A-associated microgliosis and 11 
astrogliosis, and greater levels of pre-synaptic (synaptophysin, VGLUT1) and excitatory post-synaptic 12 
(homer, PSD-95) markers compared to APP/PS1 mice expressing C3 normally (Shi et al., 2017a). 13 
Importantly, C3 absence in 16-month-old APP/PS1 mice, spared cognitive deficits as shown by 14 
enhanced spatial memory. This suggests that in AD, healthy synapses that would not normally require 15 
physiological elimination may be aberrantly targeted by the complement system for elimination, partly 16 
eliciting the cognitive decline seen in AD. 17 
Secretion of pro-inflammatory mediators by microglia is likely to occur concomitantly to 18 
phagocytosis, contributing to the AD-related synapse loss. Prolonged exposure to TNF-α in a triple 19 
transgenic AD-like model (3xTg) induced neuronal loss, microgliosis and upregulated C3 as well as 20 
intracellular A levels (Janelsins et al., 2008). In the TgCRND8 AD mouse model, C3 was also 21 
upregulated in response to another potent pro-inflammatory cytokine, IFN- (Chakrabarty et al., 2010). 22 
Additionally, in culture assays, microglial IL-6 and nitric oxide have direct synaptotoxic effects on 23 
neurons (Azevedo et al., 2013). Therefore, microglia not only can directly mediate synapse elimination, 24 
but can also prime synapses for removal through released soluble factors. 25 
The presence of the allele E4 for APOE (a major cholesterol carrier) is the strongest genetic risk factor 26 
influencing susceptibility to LOAD and it is associated with increased synapse loss (Koffie et al., 2009, 27 
2012, Liu et al., 2013; Tzioras et al., 2018) as well as complement activation (McGeer et al., 1997). 28 
Transcriptomic studies have heavily  implicated microglial APOE as a common facilitator of many AD-29 
associated conditions, including amyloidosis, tauopathy, ageing and inflammation (Ulrich et al., 2018; 30 
Kang et al., 2018; Lin et al., 2018). Specifically, microglia close to A plaques develop a disease 31 
associated phenotype and upregulate Apoe expression in a TREM2 dependent pathway (Keren-Shaul 32 
et al., 2017; Krasemann et al., 2017). APOE4 expressing mice also exhibit increased hippocampal gliosis 33 
and decreased levels of both synaptophysin and excitatory postsynaptic proteins (Zhu et al., 2012). 34 
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Crossing APOE4 mice to the 5xFAD AD-like mouse model resulted in exacerbated A-associated gliosis, 1 
presence of dystrophic neurites and IL-1 neuroinflammation (Rodriguez et al., 2014). Moreover, in 2 
human post mortem brains, the APOE4 genotype is associated with an increase in microglial markers 3 
of activation including CD68, MSR-A and CD64 and decrease in homeostatic Iba1 (Minett et al., 2016). 4 
It is, therefore, compelling to hypothesize that, in carriers of the APOE4 allele, microglia might be more 5 
prone to mediate pathological synapse loss.  6 
Astrocytes and their many functions have been extensively studied in the context of AD (Liddelow and 7 
Barres, 2017; González-Reyes et al., 2017; Perez-Nievas and Serrano-Pozo, 2018), albeit their role in 8 
synapse loss is less clear. Both human and mouse studies have reported upregulation of reactive 9 
astrocyte signatures (GFAP) in the presence of an APOE4 allele (Overmyer et al., 1999; Shi et al., 2017b; 10 
Belinson and Michaelson, 2009; Ophir et al., 2003). In a recent study, induced pluripotent stem cells 11 
from APOE4 AD patients were differentiated into astrocytes and were then genetically modified using 12 
CRISPR-Cas9 to generate an APOE3 genotype (Lin et al., 2018). This approach revealed that APOE4 to 13 
APOE3 conversion is sufficient to rescue the impaired phagocytic ability of astrocytes towards A (Lin 14 
et al., 2018). Interestingly, and unexpectedly, an allele-dependent role for APOE was also shown in 15 
respect to mediating synapse elimination, with APOE2 enhancing and APOE4 decreasing the rate of 16 
synaptic pruning by astrocytes (Chung et al., 2016). This apparent controversy might be explained if 17 
we assume that homeostatic elimination of damaged synapses occurs constantly in the healthy brain. 18 
Thus, one could speculate that ApoE4 carrier would be impaired in such glia-mediated ‘homeostatic 19 
synapse remodeling’.   20 
Only recently there was evidence of reactive astrocytes engulfing synapses in AD, with electron 21 
microscopy showing dystrophic VGLUT1-positive terminals being cleared by astrocytic endfeet in the 22 
hippocampus of APP/PS1 mice and in late stages of AD (Gomez-Arboledas et al., 2018). Whether this 23 
clearing mechanism is exacerbated in AD and contributes to excessive synaptic elimination is still under 24 
debate. The decreased phagocytic ability of reactive and APOE4-expressing astrocytes in development 25 
introduces new questions as to how these cells change in the context of AD and thus contribute to 26 
neurodegeneration.  27 
 28 
5.2 Glia implications in E/I imbalance in AD 29 
Mounting evidence from mouse model studies suggest that, in the amyloid-depositing brain, 30 
functional impairments of local neuronal circuits lead to disruption in the E/I balance, which then result 31 
in large-scale networks defects (Busche et al., 2008, Palop and Mucke, 2016, Busche and Konnerth, 32 
2016). Loss of inhibitory interneurons results in impaired oscillatory rhythm (Ramos et al., 2006; 33 
Baglietto-Vargas et al., 2010; Verret et al., 2012) leading to epileptiform activity (Vossel et al., 2016) 34 
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and network hyperexcitability (Brown et al., 2018) in a subset of AD patients. Some studies have 1 
reported reduction of inhibitory pre-synaptic VGAT and GAT1 peri-somatic terminals on pyramidal 2 
neurons close to plaques, both in AD post mortem cases and aged APP/PS1 mice (Garcia-Marin et al., 3 
2009). Others have found no such loss of inhibitory synapses in neither the same APP/PS1 model nor 4 
AD cases at comparable pathological stages; conversely, excitatory VGLUT1 boutons were found to be 5 
significantly reduced (Mitew et al., 2013, Canas et al., 2014). In the same study, A was also suggested 6 
to increase astrocyte GABA synthesis, highlighting a possible implication of astrocytes as a source of 7 
E/I imbalance in AD (Mitew et al., 2013). Microglia, too, may play an active role in compromising the 8 
equilibrium of excitatory vs. inhibitory synaptic transmission in AD, by promoting loss of selective 9 
synapses (i.e. glutamatergic vs. GABAergic). Evidence for microglia engulfing excitatory inputs in AD 10 
mouse models have been provided (Hong et al., 2016, Paolicelli et al., 2017), however, evidence for 11 
the engulfment of inhibitory connections is still lacking. Whether microglia can directly contribute to 12 
E/I imbalance in AD is currently under debate, and further studies are required to investigate this 13 
possibility. A clear implication of microglia in the AD brain has been recently underscored by the use 14 
of PET tracers in vivo, which are capable of specifically revealing the microglial component of 15 
neuroinflammation (Edison et al., 2018, Horti et al., 2019). 16 
 17 
 18 
6. Parkinson’s disease  19 
Parkinson's disease (PD) is a neurodegenerative disorder characterized by massive degeneration of 20 
nigro-striatal dopaminergic neurons, which leads to progressive motor and cognitive symptoms. It is 21 
the second most common neurodegenerative disease and affects 2-3% of the population over the age 22 
of 65 years (Poewe et al., 2017). The general term ‘parkinsonism’ refers to the ensemble of movement 23 
disorders defined by the appearance of bradykinesia, rigidity or tremor. Cognitive impairment, in 24 
addition, is an important non-motor symptom of PD, with a mean duration from clinical disease onset 25 
to dementia of about 10 years (Aarsland et al., 2011, Selnes et al., 2017). A key neuropathological 26 
hallmark of the PD brain is the abnormal deposition of intraneuronal (Lewy bodies) and intraneuritic 27 
(Lewy neurites) fibrillary aggregates, mainly composed of α-synuclein (α-syn) and referred to as Lewy 28 
pathology. α-syn inclusions, initially thought to be limited to the substantia nigra pars compacta of the 29 
striatum, have been associated with the primary cause of neuronal loss in PD (Desplats et al., 2009).  30 
However, post mortem brain examinations of patients affected by PD revealed that Lewy pathology is 31 
not only confined to the striatum, but also affects other well-defined brain regions, possibly following 32 
a progressive spreading pattern (Del Tredici et al., 2002, Beach et al., 2009, Colom-Cadena et al., 2017). 33 
Staging of Lewy pathology in PD was first proposed by Braak et al., based on histological examinations 34 
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showing the anatomical caudo-rostral progression of disease over time (Braak et al., 2003).  1 
Accumulating in vitro and in vivo evidence indicates that α-syn can undergo toxic conformational 2 
changes, spread from cell to cell, and initiate the formation of pathological aggregates, in a prion-like 3 
manner (Kordower et al., 2008, Li et al., 2008, Luk et al., 2012, Masuda-Suzukake et al., 2013). Together 4 
with the progressive stages of the disease, these data are in support of the spreading hypothesis, 5 
according to which Lewy pathology arises in specific brain nuclei and spreads to other structures 6 
through synaptic connections (Recasens and Dehay, 2014). 7 
Transgenic animal models with α-syn overexpression exhibit neuronal dysfunction in the absence of 8 
cell loss, indicating that disruptions of synaptic transmission occur as an initial event, preceding α-syn-9 
induced neuronal cell death (Janezic et al., 2013, Phan et al., 2017). Experimental evidence in fact 10 
shows that synaptic dysfunction is caused by presynaptic accumulation of α-synuclein aggregates, 11 
which impair axonal transport by affecting key proteins governing synaptic vesicle release (Kramer and 12 
Schulz‐Schaeffer, 2007, Bellucci et al., 2012, Anichtchik et al., 2013).  13 
Early synaptic dysfunction in PD has been supported by genetic evidence, with recently identified 14 
mutations in genes involved in clathrin-dependent synaptic vesicle endocytosis (SVE), such as DNAJC6 15 
(auxilin) and SYNJ-1 (synaptojanin 1), in patients with juvenile and early-onset atypical parkinsonism 16 
(Nguyen and Krainc, 2018). In these models, a central role for glia cell have been also proposed, 17 
although causative mechanisms still await further supportive evidence (Teismann et al., 2003).  18 
 19 
6.1 Microglia and astrocyte-mediated synapse impairment in PD 20 
Synapse loss in PD correlates with the pathological deposition of α-syn at the pre-synaptic site. Indeed, 21 
prolonged exposure to α-synuclein oligomers in hippocampal slices was shown to regulate synaptic 22 
transmission and impair LTP by activating NMDA receptors (Diógenes et al., 2012). Most of the studies 23 
aimed at elucidating the cellular basis of PD, have focused so far on mechanisms of neuronal 24 
dysfunction; however, PD-related genes are also expressed in astrocytes and microglia. Thus, it is likely 25 
that dysregulation of such genes may contribute to disease onset and progression via glia-mediated 26 
processes. Astrocytic roles in glucose metabolism are well described, and mutations in Parkin, PINK1, 27 
DJ-1 and LRKK2, associated with PD, have been shown to affect astrocytes function (Choi et al., 2013). 28 
Parkin is a ubiquitin ligase largely implicated in PD, however its role in modulating glial specific function 29 
has just started to be unraveled. Recent studies show that parkin loss exacerbates inflammation and 30 
promotes survival of activated microglia by inhibiting necroptosis, thus contributing to chronic 31 
neuroinflammation (Dionisio et al., 2018), whereas in astrocytes it induces endoplasmic reticulum 32 
stress. Whether such effects can negatively impact on synaptic function and mediate synapse loss, 33 
however, remains to be elucidated. Similarly, novel evidence for DJ-1 modulation of glial function are 34 
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emerging. DJ-1, encoded by PARK7 gene, is a ubiquitously-expressed multifunctional protein which 1 
regulates anti-oxidant and anti-apoptotic gene expression (Canet-Avilés et al., 2004). DJ-1 knockdown 2 
in astrocytes was shown to impair astrocyte-mediated neuroprotection in primary neurons (Mullet and 3 
Hinkle, 2009, Kim et al., 2016), whereas astrocytic over-expression of DJ-1 prevented oxidative stress 4 
and mitochondrial dysfunction, leading to enhanced neuronal survival in vitro and in vivo (Frøyset et 5 
al., 2018, De Miranda et al., 2018). On the other hand, DJ-1 has been also shown to modulate microglial 6 
function, with its deficiency impairing autophagy, reducing α-synuclein phagocytosis and inducing a 7 
constitutive pro-inflammatory activation (Meiser et al., 2016, Nash et al., 2017). Mutations in LRKK2, 8 
another multifunctional protein associated with late-onset familial PD, has been shown to affect basic 9 
glial function. For instance, pathogenic mutations impair lysosomal function in astrocytes (Henry et al., 10 
2015), and attenuate motility in microglia, preventing efficient response to brain damage (Choi et al., 11 
2015). Altogether, these findings support the implication of glial dysfunction in the synaptic 12 
impairment occurring in PD.   13 
 14 
6.2  Glial contribution to E/I imbalance in PD 15 
The pathophysiology of PD is characterized, among other features, by a prominent imbalance within 16 
striatal activity. Dopamine (DA) has excitatory effects on the projections from the striatum to the 17 
internal segment of Globus Pallidus (GP), defined as the direct pathway, acting through D1 receptors 18 
(D1Rs). The same neurotransmitter, however, exerts inhibitory effects on the projection from the 19 
striatum to the external segment of GP through D2 receptors (D2Rs), or indirect pathway (Surmeier et 20 
al., 2007). Loss of DA, therefore, has complex consequences on multiple levels. Several studies in 21 
rodents, using both pathogenic 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-22 
tetrahydropyridine (MPTP) models, have shown that the progressive loss of striatal DA leads to a 23 
significant loss of glutamatergic synapses on medium spiny neurons (MSNs) of the dorsal striatum 24 
(Ingham et al., 1989, Zaja-Milatovic et al., 2005, Day et al., 2006), and that dendritic spines are 25 
decreased and enlarged specifically in the direct pathway neurons (Nishijima et al., 2014). Overall, the 26 
loss of dopaminergic input from the substantia nigra alters the equilibrium between excitatory and 27 
inhibitory control from the basal ganglia to the motor cortex.  28 
Recent studies have highlighted the existence of subpopulations of astrocytes, with circuit-specific 29 
roles in the basal ganglia (Martin et al., 2015). Considering that both the direct and indirect pathways 30 
are fundamental for motor control, and are associated with motor deficits in Parkinson’s and 31 
Huntington’s diseases, the selective regulation of specific synapses by astrocytes may be involved in 32 
the coordinated activity of these networks in the striatal function, therefore, pointing to astrocytes as 33 
central players in these disorders (Martin el at 2015). 34 
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However, whether and how glia cells contribute to the E/I imbalance in PD remains elusive. 1 
It has recently been proposed that microglia may compensate for dopaminergic neuron loss through 2 
selective elimination of glutamatergic synapses from the subthalamic nucleus (Aono et al., 2017). By 3 
using the 6-OHDA-induced experimental Parkinsonism rat model, the authors showed a specific 4 
increase of activated microglia in the substantia nigra pars reticulata (SNr), engulfing excitatory pre‐ 5 
and post‐synaptic elements. These findings suggest that microglia may be involved in a negative 6 
feedback in the indirect pathway of the basal ganglia to compensate for the loss of dopaminergic 7 
neurons in PD pathology (Aono et al., 2017). A central role for astrocytes has also been proposed in 8 
the PD brain, based on the observation that loss of DA neurons in the substantia nigra is associated 9 
with increased density of activated astrocytes (Hirsch et al., 2003; Gomide and Chadi, 2005; Mcgeer 10 
and Mcgeer, 2008). Only recently, however, it has been shown that striatal astrocytes engulf 11 
dopaminergic debris in the 6-OHDA model (Morales et al., 2017). Interestingly, α-syn was observed 12 
within astrocytic processes already 4 hours after 6-OHDA administration, whereas the amyloid 13 
precursor protein (APP), found at synapses and accumulated in bulb-like structures of degenerating 14 
axons, was never found inside astrocytes. These findings suggest a selective engulfment of synaptic 15 
terminals by astrocytes, rather than a non-specific clearance of cellular debris (Morales et al., 2017).  16 
 17 
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7. Amyotrophic Lateral Sclerosis (ALS)  19 
ALS is caused by the breakdown of upper and lower motor neurons leading to the progressive 20 
weakness and atrophy of muscle, often resulting in respiratory failure and death within a few years of 21 
diagnosis. It is the most common form of motor neuron disease (MND), yet we still do not have a 22 
unifying theory of disease pathogenesis. Most cases (90%) are sporadic, with the remaining 10% due 23 
to known mutations in a growing number of disease-associated genes, such as c9orf72, SOD1, FUS and 24 
TDP-43 (Renton et al., 2014). Mounting evidence suggests that disconnection of the neuromuscular 25 
synapse occurs very early in the disease, with an initial toxic insult at the synapse, leading to 26 
disconnection of axons from their target cell, axonal breakdown and ultimately neuron death.  This 27 
model led to the popular “dying back” hypothesis of disease progression (Fischer et al 2004, Frey et al 28 
2000, Pun et al 2006). This process has been described at both peripheral synapses at the 29 
neuromuscular junction (NMJ) and synapses in the central nervous system, however the toxic insult at 30 
either site has yet to be identified. An alternative theory is the “dying forward” hypothesis, which 31 
posits that breakdown of primary motor neurons in the brain leads to subsequent loss of secondary 32 
motor neurons in the periphery, and thus muscular denervation. Cortical hyperexcitability has been 33 
observed early in ALS brains using a number of imaging techniques and it is known that chronic 34 
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hyperexcitability results in excitotoxicity, leading to motor neuron loss (Bae et al 2013). In strong 1 
support of hyperexcitability as an important feature, the most widely prescribed drug for ALS, Riluzole, 2 
acts by dampening excitatory synaptic activity in the brain  (Doble 1996). Given the complex 3 
heterogeneity of ALS, it is likely that both dying forward and dying back processes occur in disease, 4 
however, regardless the nature of the predominant process, they ultimately converge on synaptic 5 
dysfunction. Cell autonomous and non-autonomous pathways have been studied in both pathogenic 6 
pathways, with glia strongly implicated in ALS progression.   7 
 8 
7.1 Synaptic alterations in ALS 9 
ALS has historically been considered exclusively a motor neuron disease, with much of the early 10 
research focused on the central and peripheral components of the motor system. Recent studies, 11 
however, have revealed that ALS is a multi-system disorder, displaying striking genetic, pathological 12 
and clinical overlap with frontotemporal dementia (FTD) (Ling et al 2013). Approximately 15% of ALS 13 
cases receive a co-morbid diagnosis of FTD and another 30-40% present with milder cognitive and 14 
behavioral changes, reminiscent of FTD symptoms (Strong et al 2017). Given that synapse loss is the 15 
strongest correlate with cognitive decline in Alzheimer’s disease (Terry et al 1991), it’s interesting to 16 
note that synapse loss also associates with cognitive decline in ALS (Henstridge et al 2018), suggesting 17 
that synapse loss may be a common feature of cognitive change in diverse neurodegenerative diseases 18 
(Henstridge et al 2016).   19 
Betz cells are giant pyramidal neurons located in layer V of the primary motor cortex where they 20 
project mono-synaptically onto lower motor neurons within the spinal cord. They receive synaptic 21 
input primarily from the premotor cortex, which is important for the planning and execution of 22 
complex movement. Research has shown that synapses onto anatomically-normal Betz cells are 23 
dysmorphic in the brains of ALS patients (Sasaki & Iwata 1999). Furthermore, diverse animal models 24 
of ALS have revealed a common feature of pre-symptomatic loss of cortical synapses (Fogarty et al 25 
2016, Fogarty et al 2015, Qiu et al 2014). Lower motor neurons within the spinal cord exhibit a lower 26 
density of axo-somatic synapses in ALS (Sasaki & Maruyama 1994a, Sasaki & Maruyama 1994b), 27 
suggesting a disconnection between upper and lower motor neurons. At the periphery, loss of NMJ 28 
synapses represent one of the first anatomical changes in ALS models, occurring long before disease 29 
symptoms (Fischer et al 2004, Frey et al 2000, Pun et al 2006). Collectively, these studies show that 30 
synaptic connections throughout the motor system are vulnerable early in disease. 31 
 32 
7.2.1 Microglia-dependent loss of central synapses in ALS 33 
Mutations in superoxide dismutase 1 (SOD1), an antioxidizing enzyme, are associated with ALS. 34 
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Animal models overexpressing human mutated SOD1, display pre-symptomatic changes to cortical 1 
motor neurons, resulting in intrinsic hyperexcitability (Saba et al 2016) and an early loss of inhibitory 2 
interneurons (Clark et al 2017). Thus, it appears in SOD1 animal models of ALS, both intrinsic 3 
hyperexcitability and decreased inhibitory control play a role in cortical pathophysiology. Recent 4 
human studies using novel neurophysiological techniques have also suggested that imbalance 5 
between intracortical excitatory and inhibitory systems leads to hyperexcitability (Van den Bos et al 6 
2018). Many diverse ALS models exhibit pre-symptomatic synapse loss. SOD1 models present with 7 
early spine loss in the motor cortex, which worsens with disease progression (Fogarty et al 2015, Saba 8 
et al 2016). Mice overexpressing mutated forms of two RNA-DNA binding proteins commonly 9 
associated with ALS display overt synaptic defects: TDP-43 A315T mice have progressive loss of spines 10 
from P60-P90 compared to wild type mice (Handley et al 2017) and FUS R521G mice have a significantly 11 
lower density of mature spines in the cortex at P18 (Sephton et al 2014). While cell autonomous 12 
changes can influence neuronal morphology, glial cells also have the ability to significantly influence 13 
both excitatory and inhibitory synaptic systems via the release of toxic mediators or by direct 14 
phagocytosis of neuronal compartments, as described above. The study of microgliosis in human ALS 15 
tissue has mostly been confined to post mortem studies, which tend to show an increase in microglia 16 
number (Brettschneider et al 2012, Kawamata et al 1992). However, some studies have shown 17 
increased microglial activity in live human ALS brain, using PET imaging (Turner et al 2004, Zurcher et 18 
al 2015). Microglial activation is consistently detected in the motor cortex however one study also 19 
detected an increase in the dorsolateral prefrontal cortex and thalamus (Turner et al 2004). 20 
Interestingly, microgliosis appears to associate with disease severity (Brettschneider et al 2012, Turner 21 
et al 2004, Zurcher et al 2015), with a recent study suggesting microgliosis is specifically associated 22 
with rapid disease progression (Gorter et al 2018). Taking a data-driven approach, another recent work 23 
uncovered networks of genes that associate with motor neuron pathology in human ALS brain. The 24 
study found that most genes within the top scoring network, are expressed in microglia (Cooper-Knock 25 
et al 2017). Furthermore, TREM2 levels in the cerebrospinal fluid (CSF) of ALS patients was higher than 26 
controls and TREM2 levels positively correlated with disease duration in late stage ALS (Cooper-Knock 27 
et al 2017). This supports previous work which found an increased expression of TREM2 mRNA in 28 
human and SOD1 mouse spinal cord, and also implicated a rare variant in TREM2 (p.R47H) as a risk 29 
factor for developing ALS (Cady et al 2014). Therefore it is clear that microglia have an important role 30 
to play in ALS pathogenesis (Geloso et al 2017), but what effect are microglia having on surrounding 31 
neurons? An intricate mouse study utilizing cell-type specific expression of mutant SOD1 G93A, placed 32 
microglia in a central role for mediating ALS progression. Removing mutant SOD1 from microglia, thus 33 
returning them to a wild-type state, had no effect on disease onset, but significantly slowed late stage 34 
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progression (Boillee et al 2006). This is supported by recent work (Frakes et al 2014) showing that a 1 
toxic microglial gain of function exerts a pathological effect on neurons in ALS. Our recent work has 2 
uncovered a potential mechanism by which activated, inflammatory microglia may exert degenerative 3 
effects on neurons. TDP-43 is the main pathological hallmark of ALS, with protein aggregates found in 4 
almost 100% of ALS cases (Ling et al 2013, Neumann et al 2006). Debate surrounds whether this leads 5 
to a pathological loss of normal function or a toxic gain of function, however, when TDP-43 is 6 
specifically knocked-out of microglial cells in mice, we found that they convert to a hyper-phagocytic 7 
phenotype and ingest surrounding synapses (Paolicelli et al 2017). This links TDP-43 pathology to 8 
microglial activation and synapse loss. In human ALS brain, the presence of TDP-43 pathology in the 9 
frontal cortex is associated with a higher burden of microglial activity as evidenced by increased CD68 10 
expression (Brettschneider et al 2012, Paolicelli et al 2017). Furthermore, the presence of TDP-43 in 11 
the frontal cortex was associated with lower synapse number in one study (Henstridge et al 2018) and 12 
cognitive impairment in another (Brettschneider et al 2012). Taken together, these studies place TDP-13 
43 pathology and activated microglia at the sites of synapse loss in the ALS brain, resulting in a 14 
breakdown of neuronal function and clinical manifestation of ALS.  15 
The evidence above clearly states that synapse loss is a prominent feature in human ALS brain 16 
and in diverse ALS models. However, does a similar synaptic breakdown occur around lower motor 17 
neurons within the spinal cord? A number of early studies assessing synaptic coverage of spinal motor 18 
neurons in human post mortem tissue described synapse loss and altered morphology in remaining 19 
synapses (Ince et al 1995, Matsumoto et al 1994, Sasaki & Maruyama 1994a, Sasaki & Maruyama 20 
1994b). Similar findings are evident in the SOD1 G93A mouse model, with decreased synapses onto 21 
motor neurons in the spinal cord and decreased spine density of spinal motor neurons (Fogarty et al 22 
2017, Zang et al 2005). In the same mouse model, another study found a decrease in total synapse 23 
number onto brainstem motor neurons that manifested as a small increase in excitatory synapses and 24 
a larger decrease of inhibitory terminals (Sunico et al 2011). Taken together it is clear that synapses 25 
are lost in the brainstem and spinal cord in ALS. At approximately the same time as spines are being 26 
lost in the SOD1 G93A mouse model, microglia are proliferating in the rat SOD1 G93A model (Graber 27 
et al 2010). However, to the best of our knowledge no studies to date have assessed whether microglia 28 
may be stripping synapses in the spinal cord.  29 
A recent study has found that microglia in the spinal cord may play a neuroprotective role. 30 
When human TDP-43 was over-expressed exclusively in neurons, microgliosis in the spinal cord was 31 
mild, but when the TDP-43 was switched off with doxycycline treatment, microglia became inflamed, 32 
proliferated and selectively engulfed neuronally-derived TDP-43 (Spiller et al 2018). This has been 33 
recently confirmed in a zebrafish model of human TDP-43 over-expression, in which microglia actively 34 
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phagocytose degenerating spinal cord neurons expressing TDP-43 (Svahn et al 2018). Taken together, 1 
these studies suggest that TDP-43 in stressed neurons may act as a signal to attract phagocytic 2 
microglia to clear away aggregated TDP-43. With this in mind, it is interesting to note that TDP-43 3 
aggregates have been observed in human synapses (Henstridge et al 2018) and may act as a microglial 4 
“eat me” signal in the same way complement appears to in Alzheimer’s disease. 5 
Microglia can also exert indirect effects on neuronal and synaptic function by the release of numerous 6 
signaling molecules. There is a wealth of literature describing the increased expression of 7 
proinflammatory mediators in ALS models and patients, ranging from elevated blood levels of TNF-a 8 
in human blood to increased chemokine MCP-1 expression in SOD1 mouse models (reviewed in (Philips 9 
& Robberecht 2011). Many of these excreted molecules can directly affect neuronal physiology, such 10 
as nitric oxide (NO), reactive oxygen species (ROS) and cytokines (Henkel et al 2009), further supporting 11 
a role for microglia ALS-related synapse dysfunction. 12 
 13 
7.2.2 Astrocyte-dependent loss of central synapses in ALS 14 
Glutamate is the major excitatory neurotransmitter in the brain and its levels need to be tightly 15 
controlled at the synapse to prevent excitotoxicity. Astrocytes play a major role by actively taking up 16 
excess glutamate using glutamate transporters, EEAT1 and EEAT2 (also known as GLAST and GLT-1 17 
respectively). In SOD1 models, GLT-1 levels decrease as disease progresses (Bruijn et al 1997) and this 18 
finding is consistent in human ALS spinal cord and brain (Rothstein et al 1995). These early studies 19 
suggest that a failure in astrocytic control of synaptic glutamate may result in excitotoxicity and 20 
network imbalance, supported by a study that knocked out glial GLT-1 using oligonucleotides and 21 
discovered that animals developed a progressive motor paralysis (Rothstein et al 1996). Interestingly, 22 
crossing the SOD G93A mouse with an EAAT2 over-expressing mouse delayed axonal dystrophy and 23 
motor neuron loss but did not affect onset of paralysis or life span (Guo et al 2003). Despite this less 24 
than positive outcome, a pharmacological approach (beta-lactam antibiotic, ceftriaxone) to stimulate 25 
GLT-1 expression in SOD1 G93A mice at symptom onset, led to delayed loss of muscle strength and 26 
body weight and prolonged life by 10 days (Rothstein et al 2005). Ceftriaxone was tested in a recent 27 
clinical trial and provided some excitement after a successful Phase 2, however it failed to show clinical 28 
efficacy in Phase 3 (Cudkowicz et al 2014). It was not determined if the drug affected EAAT2 expression 29 
or function in the participants, so further work is required to assess the value in targeting glial 30 
glutamate transporters in ALS. Astrocytes also play an important trophic role through the uptake of 31 
glucose from the blood stream, which they convert into lactate and pass to neurons for the generation 32 
of glutamate (Pellerin & Magistretti 1994, Pellerin et al 1998). Lactate is shuttled from the astrocyte to 33 
the neuron in a pathway requiring the glutamate transporters mentioned above, however pre-34 
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symptomatic SOD1 G93A mice have a significantly lower amount of lactate in spinal cord homogenates 1 
and a decreased expression of GLAST (Ferraiuolo et al., 2011). This suggests a disruption in the 2 
astrocyte-neuron lactate shuttle, potentially rendering the neurons hypometabolic. 3 
Small heat shock proteins (HSPBs) are important chaperones that reduce protein misfolding 4 
and aid in misfolded protein degradation. A recent study has found that in human ALS spinal cord, 5 
rapidly progressing disease was associated with increased HSPB5 and HSPB8 in astrocytes (Gorter et 6 
al 2018). Furthermore, a recent rat model with restricted mutant human TDP-43 (M337V) expression 7 
in astrocytes, displayed a progressive paralysis due to loss of motor neurons in the spinal cord (Tong 8 
et al 2013). This strongly supports an important role for glia-derived toxicity in ALS. These studies 9 
suggest that astrocytes may become overwhelmed with misfolded protein stressors in ALS, which 10 
could affect their trophic support of neurons and synapses. While it is clear that astrocytes have an 11 
important role to play in the synaptic pathology of ALS, there are currently no studies that we are 12 
aware of showing astrocytic ingestion of synaptic terminals. It will be important to discover if 13 
astrocytes are restricted to indirect effects on synaptic dysfunction or whether they can physically strip 14 
synapses and dystrophic dendrites as observed in other diseases. 15 
Cross-talk between astrocytes and microglia also appear to play a critical role in ALS pathogenesis. In 16 
the SOD1 G93A mouse, specific knock out of SOD1 G93A from astrocytes, thus reverting them back to 17 
wild-type, had no effect on ALS onset but significantly delayed microglial activation and slowed late-18 
stage disease (Yamanaka et al 2008). This suggests that in ALS not only do microglia and astrocytes 19 
affect neuronal physiology alone, they also regulate the function of one another.  20 
 21 
7.3 Glia-dependent loss of peripheral synapses in ALS 22 
The NMJ exists as a tripartite structure, consisting of the motor nerve ending, the postsynaptic muscle 23 
cell and non-myelinating perisynaptic Schwann cells (PSCs) (Ko & Robitaille 2015). These specialized 24 
glial cells are critical for the maintenance and remodeling of adult NMJs, actively phagocytosing 25 
damaged nerve terminals and guiding regenerating nerves to their correct target (Ko & Robitaille 26 
2015). Active uptake of degenerating axonal components by Schwann cells involves the initial 27 
formation of “axosomes”, aggregates of synaptic proteins and membrane fragments that are released 28 
by the axonal tip (Bishop et al 2004). Phagocytic behaviour of PSCs is induced by signals released from 29 
degenerating motor neuron axons, resulting in engulfment of synaptic terminals at the NMJ (Duregotti 30 
et al 2015). Interestingly, in a toxin-induced neuropathy model, the toxic signals (H2O2, mitochondrial 31 
DNA and cytochrome C) are released from mitochondria within the degenerating motor nerves, 32 
supporting the role of mitochondrial dysfunction in ALS (Duregotti et al 2015, Smith et al 2017). 33 
Furthermore, the expression of numerous receptors and signaling molecules involved in regulating PSC 34 
 22 
activity is under the control of the RNA-binding protein TDP-43 (Narayanan et al 2013), suggesting that 1 
TDP-43 dysfunction can significantly impact the activity of Schwann cells at the NMJ.  2 
Given the important role of the complement system in synapse loss in AD, it is interesting to note that 3 
components of the complement system are found at the NMJ in SOD1 mouse models and human tissue 4 
(Bahia El Idrissi et al 2016, Heurich et al 2011). It will be interesting to discover if these proteins tag the 5 
synaptic terminals for engulfment, in a similar glial-dependent process as described in AD above. 6 
Paradoxically, a recent study has shown that C1q deletion exacerbates disease progression and 7 
synapse loss in a SOD1 mouse model, revealing that further study is required to understand the role 8 
of complement at peripheral synaptic function (Lobsiger et al 2013). 9 
While these intriguing studies provide a glimpse of the normal function of PSCs, little is known about 10 
their role in disease. For example, it would be important to know if disease-associated changes in PSC 11 
activity resulted in aberrant synapse loss or whether their trophic role is disrupted in disease, leading 12 
to pathogenic processes.   13 
 14 
 15 
8. Multiple Sclerosis  16 
Multiple sclerosis (MS) is an autoimmune disease characterized by oligodendroglial dysfunction (Miron 17 
et al., 2013; Kotter et al., 2006) and T-cell driven inflammation (Korn et al., 2007; Aggelakopoulou et 18 
al., 2016), resulting in demyelination of grey and white matter tracts. Loss of the myelin sheath makes 19 
axons less capable of propagating electrical signals to the synapse and renders them more vulnerable 20 
to degeneration. Typically, affected individuals present with motor deficits but signs of cognitive 21 
decline are also evident in some patients (Rao et al., 1991; Chiaravalloti and DeLuca, 2008).  Due to the 22 
demyelinating nature of MS and because the white matter is myelin-rich, changes in the grey matter 23 
have been largely over-looked, particularly in respect to synapses. Dendritic cortical spine loss, 24 
independent of cortical demyelination and axon loss, has emerged as a pathological feature of some 25 
MS patients (Jurgens et al., 2016; Nisticò et al., 2014), which may explain the cognitive deficits (Di 26 
Filippo et al., 2018). The role of microglia and astrocytes as active players in MS-associated synaptic 27 
stripping has been implied by multiple post-mortem studies but quantitative and mechanistic evidence 28 
is still elusive.   29 
 30 
8.1  Microglial and astrocyte contribution to synapse loss in MS  31 
Hippocampal microgliosis is a common feature in MS models as well as in human post-mortem 32 
samples, highlighting microglia yet again as a potential driver of synaptic loss in disease. Primarily, 33 
there are fewer pre-synaptic terminals in demyelinated MS cases (MS-D) compared to myelinated (MS-34 
 23 
M) and control cases in various regions of the hippocampus, including CA3 and CA1 (Michailidou et al., 1 
2015). Moreover, the researchers found that the levels of C1q and C3 are increased in the MS-D cases, 2 
and have shown, but not quantified, activated microglia containing pre-synaptic elements, suggesting 3 
that complement molecules -once again- may act as a synapse removal tag. C3d-expressing microglial 4 
clusters are seen in chronic MS lesions rather than the acute phases of demyelination, indicating C3d 5 
may not play a role in the initial synaptic degeneration seen in MS-D. Moreover, in the grey matter of 6 
MS post-mortem cases, C1q-positive neurons show dysmorphic nuclei, typical of cell stress, when 7 
adjacent to activated microglia clusters (Watkins et al., 2016). Together, these studies suggest a model 8 
in which C1q may act as a tag for early synaptic engulfment in MS, while neuronal C3d is internalized 9 
by microglia during phagocytosis of degenerating neuronal and synaptic debris in later phases of the 10 
disease. In addition, other members of the classical complement cascade need to be considered. 11 
Specifically, administration of oligonucleotides against C6 partially rescued the synaptophysin 12 
depletion found in experimental autoimmune encephalomyelitis (EAE) mouse model for MS.  13 
Reduction in C6 also led to decreases in the levels of IL-1β, microgliosis, myelin damage, and C9 of the 14 
membrane attack complex (MAC) (Michailidou et al., 2018). Interestingly, C9 showed a strong negative 15 
correlation to synaptophysin, meaning high levels of C9 correlate with lower levels of pre-synaptic 16 
terminals. Given that the MAC can activate subsequent pathological mediators like the NLRP3 17 
inflammasome in microglia (Laudisi et al., 2013), which allows maturation and release of IL-1β (Jo et 18 
al., 2016), it makes sense that there are lowers levels of inflammation and gliosis when C6 is inhibited. 19 
Furthermore, it has been previously discussed in the context of AD that other pro-inflammatory 20 
cytokines secreted by microglia have synaptotoxic effects, providing an alternative pathway to non-21 
contact dependent synapse loss. Astrocytes can also contribute to glutamate excitotoxicity in MS as 22 
they reduce the levels of their glutamate transporters, EAAT1 and EAAT2, in MS-D lesions (Dutta et al., 23 
2011), allowing excess levels of glutamate to surround synapses.  24 
 25 
8.2 E/I imbalance in MS and possible implication of glia 26 
Evidence of E/I imbalance has been reported in MS animal models, particularly the EAE model. 27 
Electrophysiological experiments have shown decreased excitatory post-synaptic potentials (EPSPs) in 28 
the CA1 of the hippocampus and impaired LTP in EAE mice, leading to cognitive impairments mediated 29 
by IL-1β driven inflammation (Di Filippo et al., 2013; Kim et al., 2012). This functional impairment may 30 
arise due to the downregulation of GluN2B NMDA receptor subunits in EAE mice. In contrast, there is 31 
evidence for inflammation-associated increase of LTP and reduction of LTD in EAE mice, displaying 32 
overall circuit hyperexcitation (Nisticò et al., 2014). In favor of this, a magnetic resonance spectroscopy 33 
study found increased levels of glutamate in demyelinated brain areas of MS patients (Srinivasan et 34 
 24 
al., 2005), implicating excitatory imbalance as a pathological substrate for myelin damage, preceding 1 
synapse loss (Dutta et al., 2011). Specifically, oligodendroglia are vulnerable to glutamate excitotoxicity 2 
as they express NMDA receptors (Pérez-Otaño et al., 2016) which are required for activity-dependent 3 
myelination and plasticity (Lundgaard et al., 2013). Therefore, initial hyperexcitability could result in 4 
oligodendroglial dysfunction and demyelination, ultimately rendering synapses weaker and more 5 
vulnerable to elimination, leading to later LTP impairments. 6 
However, other studies have reported synapse reduction occurring independently of demyelination 7 
(Jurgens et al., 2016, Albert et al., 2017). 8 
Researchers also found increased, rather than decreased, spine density in the somatosensory cortex 9 
of EAE mice, associated with increased VGLUT1 levels and disrupted PV+ interneuron connectivity 10 
(Potter et al., 2016). The altered excitatory-inhibitory balance in the cortex of these mice was 11 
associated with increased density of Iba1+ microglia, however no evidence of cause-effect was 12 
reported (Potter et al., 2016).  13 
The synaptic terminals assessed in the above MS and EAE studies are exclusively pre-synaptic 14 
with no distinction of excitatory or inhibitory nature. Loss of inhibitory signaling causes E/I imbalance, 15 
which has already been described here in the context of dementias but applies to MS as well. Indeed, 16 
GABA levels are reduced in the CSF of patients with MS, indicating decreased inhibition (Manyam et 17 
al., 1980). More recently, RNA sequencing from grey matter of motor cortices in MS patients showed 18 
downregulation of multiple genes that are critical to interneuron function (Dutta et al., 2006). Namely, 19 
there was downregulation of GAD67, an enzyme required for GABA synthesis pre-synaptically, and of 20 
the GABA receptor subunits α1 and β3 which are essential for GABA function post-synaptically. 21 
Furthermore, parvalbumin (PV) and cholecystokinin (CCK) levels were found to be lower in MS than 22 
controls, with PV-positive interneurons reduced by 30% in MS grey matter (Dutta et al., 2006).  23 
Reduction of axosomatic synaptic terminals was recently reported in the cerebellum of MS patients, 24 
associated with increased levels of reactive astrocytes and microglia, specifically in the dentate nucleus 25 
(Albert et al., 2017). In this study, ultrastructural examination by electron microscopy revealed 26 
evidence for astrocyte-mediated synaptic stripping (Albert et al., 2017). 27 
Altogether, these findings point toward a consistent alteration in the E/I balance in MS and encourage 28 
further investigation to better elucidating the role of glia mediated-synapse loss.  29 
 30 
 31 
9.         Conclusions 32 
Here we have summarized the contributions of glial cells in some of the most common 33 
neurodegenerative diseases, highlighting evidence for their role in synapse remodeling. In disease, 34 
 25 
glia-mediated synaptic refinement likely represents an attempt to counteract network dysfunction 1 
occurring in the early stages of the disease. In this scenario, glia selectively remove excitatory or 2 
inhibitory connections in specific brain regions, to compensate for disease-associated changes in 3 
synaptic input. On the other hand, intrinsic dysfunction of glia cells, due for instance to genetic 4 
mutations, could also play a critical causative role in the pathogenesis of the diseases, acting as a 5 
primary trigger for E/I imbalance, by inducing excessive synaptic pruning. It is tempting to speculate 6 
that similar mechanisms could occur in response to shifts in E/I balance in the developing brain, where 7 
glia-mediated synaptic alterations may lead to long lasting structural and functional defects, thus 8 
promoting the risk of developing psychiatric disorders and depression later in life (Durieux et al., 2015, 9 
Rial et al., 2016). Thus, deeper insight into the process of synapse remodeling mediated by glia cells, 10 
both in physiological and pathological conditions, will be essential for designing effective therapeutics 11 
to prevent, or at least halt synapse elimination. Such therapeutic interventions include an attenuation 12 
of the microglial response in AD pathology. For example, in two separate models of AD, the 13 
APPswe/PS1 and the 5XFAD, inhibiting the colony stimulating factor-1 receptor (CSF1R) markedly 14 
reduced microglial proliferation, rescuing synapse loss and cognitive deficits (Olmos-Alonso et al., 15 
2016; Spangenberg et al., 2016). Importantly, in neither of these studies did pharmacological inhibition 16 
of microglia influence A-plaque load, suggesting that microglial activation in AD can be synaptotoxic, 17 
via non-A mediated mechanisms. However, whether this synaptic and cognitive rescue was due to 18 
attenuating microglial driven inflammation is unclear. Microglial neurotoxic and synaptotoxic cytokine 19 
release in prodromal stages of the disease is likely to coincide with complement deposition and 20 
aberrant phagocytosis. Complement molecules deposited at synapses have been reported to be work 21 
as a powerful ‘eat me’ signal in several distinct neurodegenerative disorders. However, synapse 22 
elimination in pathological contexts could also be seen as a beneficial process, at least in the initial 23 
stages, aimed at re-establishing the E/I balance. Critical information will be provided by clinical trials 24 
currently testing a humanized anti-C1q antibody in neurodegeneration, after its safety was recently 25 
proven in both animal models and human cohorts (Lansita et al., 2017).  26 
Given that early synapse loss is a common phenotype in many neurodegenerative diseases, it raises 27 
the exciting possibility that a greater understanding of glia-mediated synapse loss may lead to a single 28 
therapeutic strategy that targets many of the world’s most devastating diseases. 29 
 30 
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Figure 1: Glial Control of Synaptic Homoeostasis 5 
Synapses exists as tri- or even quad-partite structures with glial processes in direct contact with 6 
neuronal components. Glia play important roles in regulating efficient neurotransmitter release and 7 
clearance, as well as providing trophic factors to ensure healthy function. Furthermore, during 8 
development glia prune away excess synapses and by doing so, fine-tune the excitatory/inhibitory 9 
balance within developing neuronal networks. 10 
 11 
Figure 2: Pathophysiology of Alzheimer’s Disease 12 
The build up of pathological amyloid and tau species leads to neurodegeneration via numerous 13 
autonomous and non-autonomous pathways. Glial cells release pro-inflammatory mediators and lose 14 
their ability to regulate glutamate homeostasis, leading to synaptic dysfunction. Furthermore, the 15 
synaptic accumulation of proteins from the complement system leads to glial-dependent synapse 16 
engulfment and loss.  17 
 18 
Figure 3: Pathophysiology of Parkinson’s Disease 19 
Anatomically, Parkinson’s Disease is characterised by a loss of striatal dopaminergic neurons. This can 20 
lead to disruption of excitatory and inhibitory circuits, resulting in the clinical motor symptoms. Loss 21 
of glutamatergic synapses is apparent in the striatum and aggregates of α-synuclein are observed in 22 
the brains of patients. Furthermore, evidence suggests α-synuclein accumulates at the synapse, where 23 
both astrocytes and microglia have been shown to engulf α-synuclein-containing synaptic material. 24 
 25 
Figure 4: Pathophysiology of Amyotrophic Lateral Sclerosis 26 
ALS is characterised by the breakdown of motor neurons in the motor cortex and spinal cord. Gliosis 27 
and cortical hyperexcitability are early features of the ALS brain and aggregates of TDP-43 are found 28 
in almost all patients. TDP-43 has been found at human synapses in ALS and the removal of TDP-43 29 
from microglia leads to hyperphagocytic cells that engulf synapses. Microglia have been shown to 30 
engulf neuronally-derived TDP43. Interestingly, synapse loss is an early feature of ALS and observed in 31 
both the central and peripheral nervous systems. 32 
 33 
 34 
Figure 5: Pathophysiology of Multiple Sclerosis 1 
While myelin loss is a central feature of MS pathology, it is accompanied by neurodegeneration, gliosis 2 
and immune cell (B-cells and T-cells) infiltration. Release of pro-inflammatory mediators and disrupted 3 
glutamate handling by glial cells leads to a toxic neuronal milieu. Furthermore, there is evidence that 4 
microglia are involved in complement-dependent synapse engulfment. 5 
 6 
Figure 6: Glial Influence on Excitatory/Inhibitory Balance 7 
Under physiological conditions, glial cells play important roles in the control of neuronal physiology, 8 
resulting in a well-controlled balance of excitatory/inhibitory neuronal networks. However, under 9 
pathological conditions as described in some of the diseases here, glial cells become hyperactive and 10 
damage surrounding neurons. This results in a dramatic tip of the balance depending on whether 11 
excitatory or inhibitory cells are disproportionally affected in the network. 12 
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